亚太地区机械循环支持与心脏移植现状
亚太地区晚期心衰治疗数据仍稀少,心脏移植率约0.075例/百万人口,远低于北美;机械循环支持成为替代方案,但报销政策差异限制可及性。HeartMate II为亚洲最常用持久设备,截至2015年9月9日共植入341例,4年生存率88%,最长支持6.5年。
要点
- 亚洲心脏移植率约0.075例/百万人口,远低于北美。
- HeartMate II植入341例,4年生存率88%,最长支持6.5年。
- 报销政策差异导致机械循环支持设备可及性不同。
核心结论
- 亚太地区心脏移植率极低,机械循环支持是可行替代但受限于报销政策,需加强数据报告和卫生政策倡导器官捐献。
研究设计与样本
- 基于ISHLT登记数据及亚太地区机械循环支持植入报告的描述性分析。
主要发现
- 亚洲心脏移植率约0.075例/百万人口;北美占全球人口7.5%却占2012年ISHLT登记移植的55.8%,亚洲占人口62.5%仅占5.7%。
- 截至2015年9月9日,亚太地区共植入341例HeartMate II(293例为移植前过渡,48例为目的治疗),其中日本180例;总体4年生存率88%,最长支持6.5年。
- 截至2015年底,亚太地区共植入243例HeartWare HVAD;HeartMate II是亚洲最广泛使用的持久设备,HVAD在澳大利亚最常用。
临床怎么用
- 亚太地区应加强心脏移植和机械循环支持的数据登记报告,并推动卫生政策改善器官捐献和报销。
局限性
- 亚太地区心衰及晚期治疗流行病学数据仍稀少,且缺乏亚洲心脏移植中心向ISHLT登记的报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globalization has resulted in epidemiologic transition in developing countries from infectious disease and nutritional deficiencies to non-communicable diseases. Epidemiologic data on heart failure (HF), particularly advanced HF therapy, in Asia are increasingly becoming available, although they remain sparse. Heart transplantation for advanced stage HF remains very low in Asia-approximately 0.075 heart transplants per 1 million population. North America, which comprises 7.5% of the world population, accounted for 55.8% of transplants recorded in the 2012 International Society for Heart and Lung Transplantation (ISHLT) Registry, whereas Asia, with 62.5% of the world population, accounted for 5.7% of transplants. There is also lack of reporting from heart transplant centers in Asia to the ISHLT Registry. Most transplant programs in Asia are in economically stable South East Asian countries, whereas in other parts of developing countries, the cost and health care infrastructures remain prohibitive for the development of these programs. Multi-cultural and racial factors, religious beliefs, and diverse traditions of many centuries have resulted in reluctance to organ donation. Mechanical circulatory support (MCS) is emerging as a viable alternative to transplantation, but despite technical capabilities, limitations in embracing MCS in Asia exist. Discrepant practices in the reimbursement of costly MCS therapy have led to differences in the availability of these devices to patients in the region. The HeartMate II (St. Jude Medical, Inc, St. Paul, MN) left ventricular assist device is currently the most widely used durable device in Asia, whereas the HeartWare HVAD (HeartWare, Inc, Framingham, MA) is used most often in Australia. By September 9, 2015, 341 HeartMate implants (293 as bridge to transplant and 48 as destination therapy) had been performed, of which 180 implants were in Japan. The overall 4-year survival is 88%. The longest duration of support is 6.5 years. By the end of 2015, 243 HeartWare HVADs had been implanted in Asia Pacific. There is a need for focused efforts at improving the reporting of data and intensifying health policy within the region to advocate organ transplantation. Individual governments need to take national responsibility to fulfill organ donation and transplantation needs of their populations. International collaboratives, coordinated by societies such as the ISHLT, will be essential in moving this field forward in Asia Pacific.
引用
- Sivathasan C, Lim CP, Kerk KL, et al. Mechanical circulatory support and heart transplantation in the Asia Pacific region. J Heart Lung Transplant. 2016. PMID: 28029573. doi:10.1016/j.healun.2016.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。